NNZ-2591
Also called cyclic glycine-proline
- Evidence
- Limited research
- Class
- IGF-1-related peptide
NNZ-2591 belongs to the IGF-1-related peptide class. This library groups it under brain & sleep. Its source category is In clinical trials.
At a glance
| Compound class | IGF-1-related peptide |
|---|---|
| Body system | Brain & sleep |
| Use or research focus | Phelan-McDermid; Rett; Angelman |
| Regulatory status | Investigational (Phase 2) |
| Source evidence rating | Limited research |
How does NNZ-2591 work?
Modulates IGF-1 pathway.
The source catalog maps this mechanism to Brain / CNS. A biological mechanism describes how a compound interacts with the body; it does not by itself prove a clinical benefit.
What does the evidence tell us?
The source catalog rates the evidence as limited. Laboratory and animal findings cannot establish benefits or safety in people. Small or early studies may raise useful research questions without supporting routine clinical use.
Use the Citations tab to examine the underlying sources. Look for human studies, a relevant comparison group, meaningful outcomes, and adequate follow-up. An ingredient, approved drug, and compounded preparation may have different evidence.
Safety and considerations
A compound being studied in a clinical trial is not necessarily approved or effective. Trial participants follow a study protocol with eligibility criteria and monitoring. Results from one population or formulation may not apply to another.
This library is educational and does not provide dosing or treatment instructions. A listing here does not indicate that Peppy offers the compound.
Common questions
What is NNZ-2591?
NNZ-2591 belongs to the IGF-1-related peptide class. This library groups it under brain & sleep. Its source category is In clinical trials. Its recorded use or research focus is: Phelan-McDermid; Rett; Angelman.
Is NNZ-2591 FDA-approved?
The catalog records: Investigational (Phase 2). Check the current product-specific regulatory information in the source links; a source category does not establish approval for every use or formulation.
How strong is the research?
The source catalog rates the evidence as limited. Laboratory and animal findings cannot establish benefits or safety in people. Small or early studies may raise useful research questions without supporting routine clinical use.
Where can I read the research?
The Citations tab contains 2 reference links from the source dataset. The original research guide provides additional context. These links are a starting point for reading the evidence.
More for brain & sleep
Factual catalog fields and citation links are adapted from Superpower’s NNZ-2591 guide and the public dataset linked in the reference post. Peppy’s explanations are educational; this page does not represent an independent clinical review of every linked study.
Sources & further reading
References associated with NNZ-2591 in the source dataset. Open a source to review its study design, population, limitations, and date.
View the original research guide